Search This Site:
Clinical Commissioning Groups Logo

JPC Bulletin

Bedfordshire and Luton Joint Prescribing Committee

Ref: JPC Bulletin 280
Bulletin Date: 27/09/19
Review Date: September 2021

Bulletin 280: Fluticasone/vilanterol 92/22 micrograms inhalation powder (Relvarv ®Ellipta®) for the treatment of COPD

JPC Recommendations:

  • The committee agreed to add Fluticasone/vilanterol (Relvar®Ellipta®) powder for inhalation to the formulary within its licensed indication as a 1st line choice ICS / LABA option for the treatment of COPD.

Additional Information:

Scroll to Top